7-chloro-4-hydroxyquinoline profile

7-chloro-4-hydroxyquinoline, also known as 4-hydroxy-7-chloroquinoline, is a synthetic compound that has been investigated for its potential pharmacological properties. It is a derivative of quinoline, a heterocyclic aromatic compound with a wide range of applications in pharmaceuticals, dyes, and pesticides. The compound exhibits antibacterial and antifungal activities. The compound was first synthesized in the 1950s and its synthesis involves a multi-step process starting from 4-hydroxyquinoline. Research on 7-chloro-4-hydroxyquinoline has focused on its potential as a drug candidate for treating bacterial and fungal infections. Its specific mechanism of action is under investigation, but it is believed to interfere with the growth and development of microorganisms. The compound has also been investigated for its potential to inhibit the growth of cancer cells. However, further studies are required to assess its safety and efficacy in humans.'

7-chloro-4-hydroxyquinoline: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	66593
CHEMBL ID	1409793
SCHEMBL ID	409748
MeSH ID	M0136398

Synonym
MLS000517803 ,
KUC100209
smr000129049
AKOS002683703
7-chloro-quinolin-4-ol
7-chloro-4-quinolinol
nsc38928
nsc-38928
7-chloro-4-hydroxyquinoline
4-quinolinol, 7-chloro-
86-99-7
7-chloroquinolin-4-ol ,
KUC100209N
7-chloro-1h-quinolin-4-one
A841908
NCGC00247321-01
einecs 201-715-2
nsc 38928
HMS2203H11
AKOS015998208
23833-97-8
FT-0621383
FT-0621382
MRW ,
HMS3349G17
chloroxoquinoline
7-chloroquinolin-4(1h)-one
SCHEMBL409748
7-chloro4-quinolinol
DTXSID90235344
W-104048
AE-641/13516197
7-chloro-4(1h)-quinolinone
CHEMBL1409793 ,
4MRW
mfcd00006778
23fwh4ch0u ,
7-chloro-4-keto-quinoline
unii-23fwh4ch0u
chloroxoquinoline [who-dd]
CS-W017251
Q27463509
E76575
AS-47497
CCG-321470
SY016725
AMY340
SB67538
SB67621
F13945
bdbm50532260
CS-0166875
SY296663
mfcd20542777
EN300-223987
Z1255464975
PD063051

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	3.1623	0.0032	45.4673	12,589.2998	AID2517
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	19.9526	0.0112	12.4002	100.0000	AID1030
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	3.1623	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	0.1458	0.0046	11.3741	33.4983	AID624297
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	1.1220	0.0041	9.9625	28.1838	AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)	Ki	500.0000	1.0000	1.0000	1.0000	AID1625393
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cAMP catabolic process	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cGMP catabolic process	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
negative regulation of cGMP-mediated signaling	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cAMP-mediated signaling	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
3',5'-cyclic-nucleotide phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cAMP binding	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
cGMP binding	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
metal ion binding	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activity	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1489126	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of novel 4(1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents.
AID1586123	Cytotoxicity against human RKO cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents.
AID1489123	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of novel 4(1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents.
AID1489125	Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of novel 4(1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents.
AID1489127	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of novel 4(1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents.
AID1586126	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents.
AID1379813	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1625393	Inhibition of human N-terminal His6-tagged PDE10A2 catalytic domain expressed in Escherichia coli BL21(DE3) RIL cells using 3',5'-cGMP as substrate by colorimetric assay	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1489124	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of novel 4(1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents.
AID1586124	Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents.
AID1489128	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of novel 4(1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents.
AID1379820	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1379818	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1379816	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1586128	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents.
AID1586125	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents.
AID1379821	Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1379819	Cytotoxicity against human HCT8 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1586127	Cytotoxicity against human NCI-H1650 cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents.
AID1489122	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Discovery of novel 4(1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents.
AID1586122	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents.
AID1379815	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1379814	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID1379817	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis, structure-activity relationships and preliminary mechanism of action of novel water-soluble 4-quinolone-3-carboxamides as antiproliferative agents.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2014	Journal of biomolecular screening, Apr, Volume: 19, Issue:4	Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (7.69)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.69)	29.6817
2010's	10 (76.92)	24.3611
2020's	1 (7.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	6.96	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
1-methyl-3-isobutylxanthine 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.	2.13	1	3-isobutyl-1-methylxanthine
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.13	1	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pentoxifylline [no description available]	2.13	1	oxopurine
rolipram [no description available]	2.13	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
zardaverine zardaverine: structure given in first source. zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.	2.13	1	organofluorine compound; pyridazinone	anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug
5-nitroquinoline [no description available]	2.52	2
2-amino-4,6-dimethyl pyrimidine 2-amino-4,6-dimethyl pyrimidine: structure in first source	2.52	2	aminopyrimidine
5-nitroindazole [no description available]	2.52	2
7-chloro-4-aminoquinoline 7-chloro-4-aminoquinoline: structure given in first source	6.96	1	aminoquinoline
9-(2-hydroxy-3-nonyl)adenine (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase.	2.13	1	EHNA	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor
cilomilast [no description available]	2.13	1	methoxybenzenes
rp 73401 piclamilast: an antiasthmatic agent and phosphodiesterase 4 inhibitor; structure in first source. piclamilast : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-(cyclopentyloxy)-4-methoxybenzoic acid with the primary amino group of 3,5-dichloropyridin-4-amine.	2.13	1	aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide	anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor
2-amino-4-methyl-3-nitropyridine [no description available]	2.52	2
doxorubicin hydrochloride [no description available]	2.15	1	anthracycline
rolipram (-)-rolipram : The (R)-enantiomer of rolipram.	2.13	1	rolipram
mesopram mesopram: a potent & selective type IV phosphodiesterase inhibitor	2.13	1
roflumilast [no description available]	2.13	1	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
cyclic nucleotide phosphodiesterases, type 4 [no description available]	2.13	1
baohuoside i baohuoside I: structure given in first source; isolated from the herb Epimedium davidii	2.13	1	glycosyloxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; plant metabolite
rs 25344 RS 25344: inhibits phosphodiesterase PDE-4D3; structure given in first source	2.13	1
chiniofon Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.	1.96	1
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.13	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
2-methyl-4(3h)-quinazolinone 2-methyl-4(3H)-quinazolinone: from Bacillus cereus; structure given in first source	2.52	2
4-hydroxyquinazoline 4-oxo-3,4-dihydroquinazoline: structure in first source	2.52	2	quinazolines
bay 73-6691 BAY 73-6691: potent and selective inhibitor of phosphodiesterase 9; structure in first source	2.13	1
bay 60-7550 [no description available]	2.13	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Colorectal Cancer [description not available]	2.21	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.21	1
Breast Cancer [description not available]	2.21	1
Invasiveness, Neoplasm [description not available]	2.21	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.21	1

7-chloro-4-hydroxyquinoline

Description

Cross-References

Synonyms (57)

Protein Targets (6)

Potency Measurements

Inhibition Measurements

Biological Processes (4)

Molecular Functions (7)

Ceullar Components (1)

Bioassays (38)

Research

Studies (13)

Market Indicators

Research Demand Index: 19.45

Study Types

7-chloro-4-hydroxyquinoline

Description

Cross-References

Synonyms (57)

Protein Targets (6)

Potency Measurements

Inhibition Measurements

Biological Processes (4)

Molecular Functions (7)

Ceullar Components (1)

Bioassays (38)

Research

Studies (13)

Market Indicators

Research Demand Index: 19.45

Study Types

Related Drugs (27)

Related Conditions (7)